These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

790 related articles for article (PubMed ID: 36551958)

  • 21. Management of hepatocellular in the United States.
    Mokdad AA; Hester CA; Singal AG; Yopp AC
    Chin Clin Oncol; 2017 Apr; 6(2):21. PubMed ID: 28482674
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Locoregional and systemic therapy for hepatocellular carcinoma.
    Gbolahan OB; Schacht MA; Beckley EW; LaRoche TP; O'Neil BH; Pyko M
    J Gastrointest Oncol; 2017 Apr; 8(2):215-228. PubMed ID: 28480062
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Portal Vein Tumor Thrombosis and Hepatocellular Carcinoma - The Changing Tides.
    Khan AR; Wei X; Xu X
    J Hepatocell Carcinoma; 2021; 8():1089-1115. PubMed ID: 34522691
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Immune Checkpoint Inhibitors for Advanced Hepatocellular Carcinoma: Monotherapies and Combined Therapies.
    Ouyang T; Kan X; Zheng C
    Front Oncol; 2022; 12():898964. PubMed ID: 35785169
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Hepatocellular Carcinoma].
    Schultheiß M; Bengsch B; Thimme R
    Dtsch Med Wochenschr; 2021 Oct; 146(21):1411-1420. PubMed ID: 34670284
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Hepatocellular carcinoma.
    Llovet JM; Zucman-Rossi J; Pikarsky E; Sangro B; Schwartz M; Sherman M; Gores G
    Nat Rev Dis Primers; 2016 Apr; 2():16018. PubMed ID: 27158749
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Therapeutic Management of Advanced Hepatocellular Carcinoma: An Updated Review.
    Falette Puisieux M; Pellat A; Assaf A; Ginestet C; Brezault C; Dhooge M; Soyer P; Coriat R
    Cancers (Basel); 2022 May; 14(10):. PubMed ID: 35625962
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Evidence to Date: Clinical Utility of Tremelimumab in the Treatment of Unresectable Hepatocellular Carcinoma.
    Ahmed Z; Lee SS; Victor DW; Kodali S
    J Hepatocell Carcinoma; 2023; 10():1911-1922. PubMed ID: 37915617
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Improving survival in patients with hepatocellular carcinoma related to chronic hepatitis C and B but not in those related to non-alcoholic steatohepatitis or alcoholic liver disease: a 20-year experience from a national programme.
    Hassan I; Gane E
    Intern Med J; 2019 Nov; 49(11):1405-1411. PubMed ID: 30908822
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Intermediate-advanced hepatocellular carcinoma in Argentina: Treatment and survival analysis.
    Piñero F; Marciano S; Fernández N; Silva J; Anders M; Zerega A; Ridruejo E; Romero G; Ameigeiras B; D'Amico C; Gaite L; Bermúdez C; Reggiardo V; Colombato L; Gadano A; Silva M
    World J Gastroenterol; 2019 Jul; 25(27):3607-3618. PubMed ID: 31367160
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Current and Future Systemic Therapies for Hepatocellular Carcinoma.
    Bteich F; Di Bisceglie AM
    Gastroenterol Hepatol (N Y); 2019 May; 15(5):266-272. PubMed ID: 31360140
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Hepatocellular carcinoma, novel therapies on the horizon.
    El Dika I; Makki I; Abou-Alfa GK
    Chin Clin Oncol; 2021 Feb; 10(1):12. PubMed ID: 32527116
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Non-immunotherapy options for the first-line management of hepatocellular carcinoma: exploring the evolving role of sorafenib and lenvatinib in advanced disease.
    Perera S; Kelly D; O'Kane GM
    Curr Oncol; 2020 Nov; 27(Suppl 3):S165-S172. PubMed ID: 33343210
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Transarterial Chemoembolization and Unresectable Hepatocellular Carcinoma: A Narrative Review.
    Manjunatha N; Ganduri V; Rajasekaran K; Duraiyarasan S; Adefuye M
    Cureus; 2022 Aug; 14(8):e28439. PubMed ID: 36176866
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Multimodal Treatment of Hepatocellular Carcinoma in Patients With Hepatitis C Virus Infection Treated With Direct-Acting Antivirals.
    Mercan-Stanciu A; Isac T; Rababoc R; Rusie D; Toma L; Vacaroiu IA; Tulin R; Iliescu EL
    Cureus; 2022 May; 14(5):e25487. PubMed ID: 35800821
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Advances in Management of Hepatocellular Carcinoma.
    Intaraprasong P; Siramolpiwat S; Vilaichone RK
    Asian Pac J Cancer Prev; 2016; 17(8):3697-703. PubMed ID: 27644603
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Emerging drugs for the treatment of hepatocellular carcinoma.
    Ayoub WS; Jones PD; Yang JD; Martin P
    Expert Opin Emerg Drugs; 2022 Jun; 27(2):141-149. PubMed ID: 35642526
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Targeting angiogenesis for liver cancer: Past, present, and future.
    Zhu XD; Tang ZY; Sun HC
    Genes Dis; 2020 Sep; 7(3):328-335. PubMed ID: 32884987
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Hepatocellular carcinoma in non-alcoholic fatty liver disease-a review of an emerging challenge facing clinicians.
    Geh D; Manas DM; Reeves HL
    Hepatobiliary Surg Nutr; 2021 Jan; 10(1):59-75. PubMed ID: 33575290
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Etiopathogenetic Factors of Hepatocellular Carcinoma, Overall Survival, and Their Evolution over Time-Czech Tertiary Center Overview.
    Hříbek P; Klasová J; Tůma T; Kupsa T; Urbánek P
    Medicina (Kaunas); 2022 Aug; 58(8):. PubMed ID: 36013566
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 40.